Kieckhefer Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Kieckhefer Group’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$198K	Sell	48,000 -26,000	-35%	-$88.1K	0.08%	59
2026 Q2	$272K	Hold	74,000	–	–	0.11%	58
2026 Q1	$227K	Hold	74,000	–	–	0.11%	53
2025 Q4	$303K	Hold	74,000	–	–	0.14%	41
2025 Q3	$361K	Buy	74,000 +36,000	+95%	+$189K	0.17%	38
2025 Q2	$192K	Buy	+38,000	New	+$187K	0.1%	44

Other funds holding RXRX

GAA

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

CCIA

Cherry Creek Investment Advisors Englewood, Colorado $261M AUM 29.65% 1-Year Est. Return

WWM

Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return

AWM

Accel Wealth Management Waverly, Iowa $464M AUM 21.88% 1-Year Est. Return

Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

TWM

TriaGen Wealth Management Calabasas, California $413M AUM 35.91% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

QPBE

Quintet Private Bank (Europe) Luxembourg $2.28B AUM 23.89% 1-Year Est. Return

Kieckhefer Group's RXRX Position: Q3 2026 in Review

Kieckhefer Group reduced its Recursion Pharmaceuticals (RXRX) stake by 35% in Q3 2026, selling an estimated $88.1K and leaving 48,000 shares worth $198K. The position accounts for 0.08% of the portfolio, ranked #59.

Kieckhefer Group first reported a position in RXRX in Q2 2025 and has held it in 6 quarters since. The position peaked at $361K in Q3 2025. 20 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

Kieckhefer Group held 48,000 shares of Recursion Pharmaceuticals worth $198K as of Q3 2026.
Kieckhefer Group sold 26,000 Recursion Pharmaceuticals shares in Q3 2026, an estimated $88.1K.
Recursion Pharmaceuticals made up 0.08% of Kieckhefer Group's portfolio in Q3 2026, its #59 holding.
Kieckhefer Group first reported a position in Recursion Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
Kieckhefer Group's Recursion Pharmaceuticals position peaked at $361K in Q3 2025.
20 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Kieckhefer Group's 13F filing for Q3 2026, filed 13 Oct 2026.